Qol Holdings (3034) Q2 2026 earnings summary

Executive summary

• Achieved record-high sales and profit for the six months ended September 30, 2025, with consolidated net sales up 14.0% year-over-year to ¥142,230 million, operating profit up 17.8% to ¥7,182 million, and profit attributable to owners of parent up 192.7% to ¥3,547 million.

• EBITDA increased 19.9% year-on-year to ¥11,916 million, reflecting strong operational performance across segments.

• Growth was driven by strong performance in the pharmaceutical manufacturing business, especially from DAIICHI SANKYO ESPHA, and steady contributions from the pharmacy and BPO contracting businesses.

• The company increased its stake in DAIICHI SANKYO ESPHA to 80% in April 2025, further enhancing group synergies.

• The Japanese economy showed moderate recovery, but uncertainty remains due to private consumption slowdowns and global trade policy impacts.

Financial highlights

• Net sales rose 14.0% year-over-year to ¥142,230 million; operating profit increased 17.8% to ¥7,182 million; EBITDA grew 19.9% to ¥11,916 million.

• Profit attributable to owners of parent surged 192.7% year-over-year to ¥3,547 million; EPS rose 191.4% to ¥94.51.

• Gross profit for the period was ¥20,119 million, up from ¥19,049 million year-on-year.

• Ordinary profit increased 16.7% year-on-year to ¥7,257 million.

• Free cash flow improved significantly to ¥5,168 million from ¥742 million in the prior year.

Outlook and guidance

• As of 2Q FY3/2026, the company achieved 50.8% of its full-year net sales forecast and 46.3% of its operating profit forecast.

• Full-year targets for FY3/2026 are net sales of ¥280,000 million, operating profit of ¥15,500 million, and EPS of ¥186.51.

• Full-year forecast for FY2026 projects profit attributable to owners of parent of ¥7,000 million (up 35.5%).

• Annual dividend forecast is ¥46.00 per share.

• Medium-term plan targets consolidated net sales of ¥500 billion, operating profit of ¥35 billion, and ROE of 15% by 2030.